Vical Within Days of Prototype H1N1 Vaccine
San Diego’s Vical (NASDAQ: VICL) said today it has the necessary genetic sequence and plans to produce a prototype vaccine for the H1N1 influenza, aka Swine Flu, “within the next few days.” Yesterday, Vical announced it has entered into an agreement with the U.S. Naval Medical Research Center (NMRC), a biomedical research organization within the U.S. Navy, for the expedited development of a Swine Flu vaccine. The goal is to get the vaccine into clinical testing as quickly as possible.
Trending on Xconomy
By posting a comment, you agree to our terms and conditions.